United States: FDA CBD Roundup: Agency Continues Existing Enforcement Approach While Reviewing Public Comments And Considering Future Policy Approaches

On May 31, 2019, the U.S. Food and Drug Administration (“FDA”) held a much-anticipated public hearing regarding “Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds.” Since that time, FDA has reiterated its existing regulatory and enforcement approach to products containing cannabidiol (“CBD”) while also evaluating other science-based policy approaches for CBD products. The agency has emphasized that it is aiming to protect patients and the public health, foster innovation for safe and appropriate products, and promote consumer confidence.

FDA’s actions follow the enactment of the 2018 Farm Bill. As Ropes & Gray previously reported (see Alert and podcast), the 2018 Farm Bill removed hemp—defined as cannabis and cannabis derivatives with concentrations of THC no more than 0.3%—from the definition of marijuana in the Controlled Substances Act (“CSA”). This legislation meant that hemp, including CBD derived from hemp, was no longer unlawful under the CSA. However, the 2018 Farm Bill expressly preserved FDA’s authority to regulate such products.

This Alert summarizes the following recent developments related to FDA’s regulation of CBD products:

  1. Public Comments: The closing of the comment period on July 16, 2019 for FDA’s public hearing docket, with nearly 4500 comments submitted;
  2. Recent FDA Warning Letter: FDA’s issuance of a warning letter on July 22, 2019, to a firm marketing CBD products with unsubstantiated disease claims; and
  3. FDA Testimony: Testimony of FDA’s Principal Deputy Commissioner, Amy Abernethy, before the Senate Committee on Agriculture, Nutrition, and Forestry on July 25, 2019.

1. Public Comments Reveal Diversity of Perspectives and Range of Significant Policy Issues

FDA’s public hearing docket received 4,492 comments from a diverse range of stakeholders. The majority of commenters were individual consumers who support FDA regulation that promotes broad availability of CBD and other cannabis-derived products. Additionally, various trade organizations, patient and consumer advocacy organizations, research organizations, cannabis and cannabis-derived product manufacturers, law firms, and businesses with a stake in the cannabis and cannabis-derived product market submitted comments. The majority of these comments generally supported regulation that would allow for greater accessibility in the marketplace, but with appropriate controls to ensure safety and quality. Most commenters agreed that the FDA must provide additional guidance and clarification as to how products may be legally manufactured and marketed.

Below is a summary of key issues raised by commenters relating to: (a) FDA regulation and policy generally, (b) health and safety risks, (c) manufacturing and product quality, (d) marketing, labeling, and sales, (e) product benefits, and (f) economic and cost considerations.

A. FDA Regulation and Policy Generally

  • Many comments highlighted the need for clarity in the regulatory framework, including with respect to labeling and packaging, manufacturing standards, and product testing standards, among other matters.
  • Comments noted that the 2018 Farm Bill has led to confusion about which hemp products are legal, and the current patchwork of state laws is difficult for companies and consumers to navigate.
  • Numerous comments supported regulations policies that would legalize CBD-containing dietary supplements and foods. Several comments thought FDA’s existing new dietary ingredient notification system would provide reasonable assurance that CBD does not present a significant or unreasonable risk in dietary supplements.
  • Several comments recommended that FDA exercise enforcement discretion regarding the “exclusionary clause” provisions on which FDA bases its position that CBD cannot legally be added to foods or marketed in dietary supplements.
  • Various comments urged FDA to establish policies that would encourage more research on CBD and other cannabis-derived products.

B. Health and Safety Risks

  • Comments expressed concern with the unknown impact CBD can have on special populations, such as pregnant women, nursing women, and children. Pharmaceutical companies were concerned about the unknown interaction that CBD may have with different prescription drugs. However, other commenters pointed to a recent World Health Organization (“WHO”) report regarding CBD and the clinical studies of Epidiolex, an FDA-approved form of CBD, to emphasize the overall safety of CBD.
  • Commenters raised concern with the lack of oversight for the vast array of CBD products on the market and the potential that they may be of low quality. Undocumented pesticides, heavy metals, residual solvents, and microbial contamination were all cited as potential concerns.

C. Manufacturing and Product Quality

  • Commenters expressed concern that the lack of uniform regulation and clear oversight by FDA has led to poor quality products on the market and resulted in consumer distrust and confusion.
  • Many comments recommended that FDA establish standards for manufacturing CBD and other cannabis-derived products. Several commenters explained that FDA’s existing regulatory framework is adequate to address manufacturing and product quality concerns. For example, comments suggested that current good manufacturing practice requirements be applied to manufacturing of CBD products and that FDA inspect manufacturing facilities.
  • Testing laboratories recommended that FDA establish standards for product testing (e.g., testing of THC content) to ensure consistency across jurisdictions.

D. Marketing, Labeling, and Sales

  • Commenters asserted that the lack of standardized labels and terminology in the CBD industry has led to consumer confusion and distrust. For example, one comment noted that the terms “hemp oil,” “CBD,” “CBD extract,” “hemp extract,” and similar words are all being used in the marketplace with no clear standards for what these terms mean.
  • Commenters also expressed concern that the labels of CBD-containing products may not accurately reflect the amount of CBD contained in the products.
  • Comments also recommended that labels address the potential for adverse events and discuss risks of specific drug interactions with CBD.

E. Product Benefits

  • The majority of comments from individual consumers highlighted the benefits of using cannabis and cannabis-derived products. Individuals provided anecdotes about how CBD products had helped with various ailments, including anxiety, depression, PTSD, brain cancer and pain.
  • Individual consumers and health care professionals also cited scientific journal articles purportedly demonstrating the efficacy of CBD and other cannabis-derived products in treating various medical conditions.

F. Economic and Cost Considerations

  • Some commenters discussed the positive impact that CBD and other cannabis-derived products would have on the national economy if they were more widely available.
  • Some individual consumers commented that CBD products are less expensive than prescription drugs and worried that prices may increase if the products are subject to more regulation.

2. New Warning Letter Continues FDA’s Existing Approach to CBD Enforcement

During the May 31 public hearing, Acting FDA Commissioner Ned Sharpless reiterated the agency’s current policy for products containing CBD. Specifically, FDA takes the position that under current law, CBD cannot lawfully be added to a food or marketed as a dietary supplement. Additionally, FDA’s “biggest concern” is the marketing of CBD products with disease claims that put the health of consumers at risk. Nevertheless, FDA has made clear that the agency does not have a policy of enforcement discretion with respect to any CBD products.

A warning letter issued to Curaleaf on July 22 and announced by FDA on July 23 continues this approach. Among other concerns, FDA cited the firm’s marketing of a CBD-containing lotion, pain relief patch, tincture, vape pen, and pet food with various disease claims, including claims on the Company’s website and social media accounts that the products could treat cancer, Alzheimer’s disease, Parkinson’s disease, opioid withdrawal, ADHD, chronic pain, and pet anxiety. Because of these disease claims, FDA considered the products to be unapproved drugs in violation of the Federal Food, Drug, and Cosmetic Act (“FDCA”). Additionally, FDA explained that the firm’s CBD-containing products could not legally be marketed as dietary supplements.

The new warning letter is similar to numerous prior warning letters the FDA has issued for CBD-containing products since 2015. However, it demonstrates the need for firms marketing CBD-containing products to review all claims and marketing statements carefully. For example, a CBD-containing product that purports to be a cosmetic (e.g., topical lotion) will nevertheless be considered an unapproved drug by FDA if the product is marketed with disease claims. While FDA is evaluating potential changes to its CBD-related policies, FDA will take action against firms based on its current regulatory approach.

3. In Senate Testimony, FDA Emphasizes Caution in Its Efforts to Develop Additional Regulatory Pathways for CBD

On July 25, 2019, FDA’s Principal Deputy Commissioner, Amy Abernethy, testified before the Senate Committee on Agriculture, Nutrition, and Forestry to summarize the agency’s efforts to develop a CBD regulatory policy. Dr. Abernethy echoed the agency’s consistent position regarding the regulatory status of hemp-derived products, including those that contain CBD and other cannabinoid compounds, in the wake of the 2018 Farm Bill.

Dr. Abernethy discussed the goals of FDA’s high-level CBD Policy Working Group, which is considering the appropriateness of potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed. She described the working group’s “first priority” as obtaining and assessing safety data unique to including CBD in food and dietary supplement products as opposed to CBD as an active ingredient in a drug product. Specifically, FDA will evaluate the safety of potentially exposing a wide range of consumers to such products, including pregnant or nursing mothers, children, the elderly, those with chronic illnesses, and those taking medications that might interact with CBD. The working group is also concerned with potentially unsafe manufacturing processes for CBD products and product labeling that lists inaccurate concentrations of CBD or fails to list other potentially dangerous compounds contained in the products.

Dr. Abernethy acknowledged that the FDCA permits FDA to adopt regulations that create exceptions to the legal provisions that currently prohibit CBD from being added to foods or marketed as a dietary supplement. However, she noted that even an expedited rulemaking process can take three to five years under the Administrative Procedure Act. Summarizing the agency’s concerns, Dr. Abernethy emphasized that “FDA will only consider creating legal pathways for CBD to be marketed as a dietary supplement or in a food if the Agency is confident that it can develop a framework that addresses safety concerns.” FDA previously stated in its July 23 press announcement that it plans to report on the progress of its CBD Policy Working Group by early fall 2019.


As these developments demonstrate, FDA has many significant issues to evaluate as it reviews public comments and considers future regulatory pathways for CBD-containing products. Yet in the meantime, FDA will not hesitate to take regulatory action through the issuance of warning letters against firms making unsupported, unapproved disease claims for CBD-containing products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions